Date search

Top news

  • NovaMedica signed an agreement with Bayer on transfer of exclusive rights to its product


    Russian pharmaceutical company NovaMedica (part of the RUSNANO portfolio) and the corporation Bayer signed an agreement to provide Bayer with an exclusive license to commercialization of an innovative product developed by NovaMedica, including its manufacturing and promotion.

  • R&D Center NovaMedica Innotech joined Avifavir production efforts in Russia


    R&D Center NovaMedica Innotech (subsidiary of the pharmaceutical company NovaMedica, investment project of RUSNANO) announced release of the first commercial batch of the anti-COVID drug Avifavir® under the partnership with Kromis LLC, joint venture of the Russian Direct Investment Fund (RDIF) and the company ChemRar. NovaMedica Innotech will manufacture 100,000 units of Avifavir per month.

Read more

Media about us

All publications

Our news

All news

Industry news

All industry news